Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 3, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Psoriatic arthritis screening tools.

Abrar A Qureshi1, Patrick Dominguez, Kristina C Duffin

  • 1Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. abrar.qureshi@channing.harvard.edu

The Journal of Rheumatology
|July 9, 2008
PubMed
Summary

Psoriatic arthritis (PsA) screening tools were developed and validated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). These tools aim to improve PsA detection and clinical data collection for better patient outcomes.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitiligo and TikTok: Content quality analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Preventing cancer requires more than a list of carcinogens.

Nature·2026
Same author

Assessment of mental health disorders among patients with lichen simplex chronicus.

The British journal of dermatology·2026
Same author

Breaking the cycle: successful long-term remission of chronic erythema multiforme with rituximab therapy.

Skin health and disease·2026
Same author

The impact of vitiligo on pregnancy and perinatal outcome: a systematic review and meta-analysis.

The British journal of dermatology·2025
Same author

Alcohol Consumption and Melanoma in a Prospective United States Cohort Study: Results from the NIH-AARP Diet and Health Study.

The Journal of nutrition·2025

Area of Science:

  • Rheumatology
  • Dermatology
  • Clinical Epidemiology

Background:

  • Psoriatic arthritis (PsA) is a progressive inflammatory condition linked to psoriasis, often causing joint damage and disability if diagnosis is delayed.
  • Early detection and intervention are crucial for managing PsA and preventing long-term physical impairment.

Purpose of the Study:

  • To introduce and summarize the development and validation of three new screening tools for PsA.
  • To facilitate earlier identification of PsA in clinical practice and research settings.

Main Methods:

  • The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) led the development and validation process.
  • Key aspects of the development and validation were discussed at the GRAPPA annual meeting in Boston, September 2007.

Related Experiment Videos

Last Updated: Jul 3, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Main Results:

  • Three validated screening tools for PsA were developed.
  • These tools are designed to enhance PsA detection rates and aid in clinical data acquisition.

Conclusions:

  • The validated PsA screening tools offer a valuable resource for clinicians.
  • Effective screening can improve PsA diagnosis, prevalence assessment, and therapeutic monitoring.